Literature DB >> 10607290

Chagasic patients develop a type 1 immune response to Trypanosoma cruzi trans-sialidase.

M Ribeirão1, V L Pereira-Chioccola, L Rénia, A Augusto Fragata Filho, S Schenkman, M M Rodrigues.   

Abstract

Infective forms of Trypanosoma cruzi, the parasite that causes Chagas' disease, express on their surface an enzyme denominated trans-sialidase (TS). The present study was designed to evaluate the naturally acquired immune responses to a bacterial recombinant protein representing the catalytic domain of TS in chronically infected chagasic individuals. The cellular immune response was measured by in-vitro T-cell proliferation and by interferon (INF)-gamma, interleukin (IL)-4 and IL-10 production in response to a whole-parasite homogenate and the recombinant protein. The peripheral blood mononuclear cells of 78.6% of 28 chagasic patients responded to the recombinant protein as estimated by T-cell proliferation. With respect to cytokine production, 88% of the cells of the chagasic individuals produced IFN-gamma on stimulation with the recombinant protein. In contrast, IL-4 or IL-10 were minimally produced in response to TS. The cellular immune response was specific because most healthy individuals never exposed to T. cruzi failed to react with this recombinant protein. The plasma of 71.4% or 100% of chagasic patients had IgG antibodies as determined by ELISA or by the presence of TS inhibitory antibodies, respectively. We conclude that the catalytic domain of TS is recognized by IFN-gamma producing type 1 cells and antibodies in a large proportion of patients infected with T. cruzi.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10607290     DOI: 10.1046/j.1365-3024.2000.00260.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  24 in total

1.  Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.

Authors:  Vera Lucia Pereira-Chioccola; Abilio Augusto Fragata-Filho; Antonio Marcos de Apparecida Levy; Mauricio M Rodrigues; Sergio Schenkman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

2.  Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients.

Authors:  Juliana A S Gomes; Lilian M G Bahia-Oliveira; Manoel Otávio C Rocha; Solange C U Busek; Mauro M Teixeira; João Santana Silva; Rodrigo Correa-Oliveira
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8(+) T cell epitopes.

Authors:  Christopher S Eickhoff; Daniel Van Aartsen; Frances E Terry; Sheba K Meymandi; Mahmoud M Traina; Salvador Hernandez; William D Martin; Leonard Moise; Annie S De Groot; Daniel F Hoft
Journal:  Hum Vaccin Immunother       Date:  2015-06-24       Impact factor: 3.452

4.  Evaluation of the immune response against Trypanosoma cruzi cytosolic tryparedoxin peroxidase in human natural infection.

Authors:  Magalí C Girard; Gonzalo R Acevedo; Lucía López; Micaela S Ossowski; María D Piñeyro; Juan P Grosso; Marisa Fernandez; Yolanda Hernández Vasquez; Carlos Robello; Karina A Gómez
Journal:  Immunology       Date:  2018-08-03       Impact factor: 7.397

5.  T-Cell Immunophenotyping and Cytokine Production Analysis in Patients with Chagas Disease 4 Years after Benznidazole Treatment.

Authors:  Mauricio Llaguno; Marcos Vinicius da Silva; Lara Rocha Batista; Djalma Alexandre Alves da Silva; Rodrigo Cunha de Sousa; Luiz Antonio Pertili Rodrigues de Resende; Valdo Jose Dias da Silva; Eliane Lages-Silva; Carlo José Freire Oliveira; Juliana Reis Machado; Denise Bertulucci Rocha Rodrigues; Dalmo Correia; Virmondes Rodrigues
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

6.  Trans-sialidase Protein as a Potential Serological Marker for African Trypanosomiasis.

Authors:  Ana Filipa Teixeira; João Gomes Pereira; Sónia Pestana-Ascensão; Marcelo Sousa Silva
Journal:  Protein J       Date:  2019-02       Impact factor: 2.371

7.  Cellular immune response from Chagasic patients to CRA or FRA recombinant antigens of Trypanosoma cruzi.

Authors:  Virginia M B Lorena; Alinne F A Verçosa; Raquel C A Machado; Lucas Moitinho-Silva; Maria G A Cavalcanti; Edimilson D Silva; Antonio G P Ferreira; Rodrigo Correa-Oliveira; Valéria R A Pereira; Yara M Gomes
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

8.  Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10

9.  Humoral and cellular immune responses to Trypanosoma cruzi-derived paraflagellar rod proteins in patients with Chagas' disease.

Authors:  Vladimir Michailowsky; Keith Luhrs; Manoel Otávio C Rocha; David Fouts; Ricardo T Gazzinelli; Jerry E Manning
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

10.  Deficient regulatory T cell activity and low frequency of IL-17-producing T cells correlate with the extent of cardiomyopathy in human Chagas' disease.

Authors:  Paulo Marcos Matta Guedes; Fredy Roberto Salazar Gutierrez; Grace Kelly Silva; Renata Dellalibera-Joviliano; Gerson Jhonatan Rodrigues; Lusiane Maria Bendhack; Anis Rassi; Anis Rassi; André Schmidt; Benedito Carlos Maciel; José Antonio Marin Neto; João Santana Silva
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.